

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

March 5, 2020

Ann Rhoads Chief Financial Officer Forty Seven Inc. 1490 O'Brien Drive, Suite A Menlo Park, CA 94025

Re: Forty Seven Inc.

Form 10-Q

Exhibit No. 10.1 - Exclusive License and Collaboration Agreement, dated July 10, 2019

by and between Forty Seven, Inc. and Ono Pharmaceutical Co., Ltd.

Filed November 12, 2019

File No. 001-38554

Dear Ms. Rhoads:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance